Eine Plattform für die Wissenschaft: Bauingenieurwesen, Architektur und Urbanistik
Phase II Study of Intravenous DX‐8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan
Phase II Study of Intravenous DX‐8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan
Phase II Study of Intravenous DX‐8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan
VERSCHRAEGEN, C. F. (Autor:in) / LEVENBACK, C. (Autor:in) / VINCENT, M. (Autor:in) / WOLF, J. (Autor:in) / BEVERS, M. (Autor:in) / LOYER, E. (Autor:in) / KUDELKA, A. P. (Autor:in) / KAVANAGH, J. J. (Autor:in)
Annals of the New York Academy of Sciences ; 922 ; 349-351
01.12.2000
3 pages
Aufsatz (Zeitschrift)
Elektronische Ressource
Englisch
Elsevier | 1984
|Laparoscopic tubal sterilization—complications
Elsevier | 1980
Europäisches Patentamt | 2023
|